MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
89.34
-2.20
-2.40%
Closed 18:28 12/17 EST
OPEN
91.41
PREV CLOSE
91.54
HIGH
92.54
LOW
88.38
VOLUME
821.79K
TURNOVER
0
52 WEEK HIGH
96.54
52 WEEK LOW
33.70
MARKET CAP
5.59B
P/E (TTM)
141.52
1D
5D
1M
3M
1Y
5Y
1D
Protagonist Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 17h ago
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $108
Benzinga · 17h ago
Protagonist Therapeutics price target raised to $108 from $88 at Barclays
TipRanks · 1d ago
PROTAGONIST THERAPEUTICS <PTGX.O>: BARCLAYS RAISES TARGET PRICE TO $108 FROM $88
Reuters · 1d ago
Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
TipRanks · 1d ago
Weekly Report: what happened at PTGX last week (1208-1212)?
Weekly Report · 3d ago
Chasing Bubbles And Riding Value In Another Year Leading The S&P 500
Seeking Alpha · 3d ago
Protagonist Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 12/08 19:53
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.